Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

First Edition

Research Article May 7 2025
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results
Research Article May 7 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement.
Research Article May 7 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS
Research Article May 7 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Letter May 7 2025
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity
Research Article May 7 2025
Clec12a is required for the pathogenesis of NUP98::NSD1 AML
Research Article May 7 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
Letter May 7 2025
Dysregulated immune proteins in plasma in the UK Biobank predict Multiple Myeloma 12 years before clinical diagnosis
Research Article May 2 2025
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial
Research Article May 2 2025
Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation
Research Article May 2 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Reply May 2 2025
Clarifying the Role of p.Gln723Lys in hTTP Prevalence
Research Article May 2 2025
NTRK1-rearranged histiocytosis: clinicopathologic and molecular features
Research Article May 1 2025
Use of the Microfluidic Impedance Red Cell Assay (MIRCA) in Sickle Cell Disease
Research Article May 1 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas
Letter May 1 2025
Interpretation of Response in BOS-the Definitions Remain Key
Letter May 1 2025
Targeting Siglec-Sialic Acid Checkpoint to Reverse Immune Dysfunction Mediated by Plasmacytoid Dendritic Cells in Myeloma
Letter May 1 2025
Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term Results
Research Article May 1 2025
Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study
Research Article April 30 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703
Research Article April 30 2025
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
Research Article April 30 2025
Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma
Research Article April 30 2025
Predictive Value of Free Light Chain Burden in Patients with AL Amyloidosis Treated with Bortezomib-Based Regimens
Research Article April 30 2025
Lymphoma B cells remodel bone marrow stromal cells into extracellular matrix-producing cancer-associated fibroblasts
Letter April 29 2025
High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter's Syndrome
Review Article April 29 2025
Chronic kidney disease in adults with sickle cell trait: A systematic review and meta-analysis
Letter April 29 2025
Reassessing the Villalta Score's Use of Signs and Symptoms
Review Article April 24 2025
Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment
Review Article April 24 2025
An Ethical Allocation Scheme for Scarce Gene Therapies in Sickle Cell Disease and Transfusion-Dependent β-Thalassemia
Review Article April 24 2025
2025 ASH ISTH NBDF WFH Monitoring Report on Their 2021 Guidelines on Diagnosis and Management of von Willebrand Disease
Letter April 24 2025
Frontline allo-SCT in MRD-negative, intermediate-risk AML
Research Article April 23 2025
Statin use and survival in SLL/CLL treated with ibrutinib: Pooled analysis of four randomized controlled trials
Research Article April 23 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma
Research Article April 23 2025
Genetic deregulation of REL in germinal center B-cells induces generation of a pool of lymphoma precursor cells
Letter April 23 2025
T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia
Letter April 23 2025
RBC Transfusion Dependency Refines the Molecular International Prognostic Scoring System for Myelodysplastic Syndrome
Research Article April 18 2025
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial
Research Article April 18 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP
Letter April 18 2025
LNS-8801 as a therapeutic agent for aggressive lymphomas: ROS-induced cytotoxicity and synergy with existing therapies
Research Article April 18 2025
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patients
Research Article April 18 2025
Delayed T cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults
Research Article April 18 2025
Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and Azacytidine
Research Article April 18 2025
Genome-wide association study of somatic GATA1s mutations in newborns with Down Syndrome
Research Article April 16 2025
Evaluating the Long-Term Benefits of Hydroxyurea in Pediatric Sickle Cell Anemia
Research Article April 16 2025
Expression and treatment of ROR1+ cells with bispecific T cell engagers in pediatric acute lymphoblastic leukemia
Research Article April 16 2025
Molecular inflammatory expression profiles associated with the frequency of pain in individuals with sickle cell disease
Research Article April 16 2025
Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma
Research Article April 16 2025
Red blood cell aggregation within a blood clot causes platelet-independent clot shrinkage
Research Article April 16 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Research Article April 16 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort
Page 1 of 4
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals